Who
Marsha Fanucci
Director
Company insider
Files Form 4 as: Director, Generate Biomedicines; Director, Syros Pharmaceuticals; Director, Alnylam Pharmaceuticals; Director, Forma Therapeutics Holdings; Director, Cyclerion Therapeutics; Director, Ironwood Pharmaceuticals; Director, Momenta Pharmaceuticals; SVP, Chief Financial Officer, Millennium Pharmaceuticals.
In numbers
- Trades disclosed
- 142
- Buys
- 3
- Sells
- 14
- Bought
- $355K
- Sold
- $10.2M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 15 Sep 2005
- Last trade
- 26 Feb 2026
- Last filed
- 2 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,561 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,561 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Syros Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Syros Pharmaceuticals | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | Syros Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | Syros Pharmaceuticals | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 18 May 2023filed 19 May 2023 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,454 at $0.00 | filing |
| 23 Feb 2023filed 27 Feb 2023 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —136 at $0.00 | filing |
| 23 Feb 2023filed 27 Feb 2023 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —136 at $0.00 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —14,026 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —28,053 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —17,533 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —8,375 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code D | —6,750 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdings | SEC FORM 4 Code U | —52,532 | filing |
| 14 Oct 2022filed 14 Oct 2022 | Forma Therapeutics Holdings | SEC FORM 4 Code U | —7,250 | filing |
| 16 Sep 2022filed 19 Sep 2022 | Syros Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 16 Sep 2022filed 19 Sep 2022 | Syros Pharmaceuticals | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | Cyclerion Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | Forma Therapeutics Holdingsoption or derivative | SEC FORM 4 Code A | —6,750 at $0.00 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Marsha Fanucci; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.